Wall Street analysts expect Stericycle Inc (NASDAQ:SRCL) to report sales of $886.19 million for the current fiscal quarter, Zacks reports. Eight analysts have made estimates for Stericycle’s earnings, with estimates ranging from $858.50 million to $918.90 million. Stericycle posted sales of $906.40 million during the same quarter last year, which would indicate a negative year over year growth rate of 2.2%. The company is scheduled to report its next earnings report on Wednesday, February 21st.
On average, analysts expect that Stericycle will report full year sales of $886.19 million for the current fiscal year, with estimates ranging from $3.55 billion to $3.61 billion. For the next financial year, analysts anticipate that the firm will post sales of $3.65 billion per share, with estimates ranging from $3.57 billion to $3.77 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow Stericycle.
Stericycle (NASDAQ:SRCL) last issued its earnings results on Wednesday, November 8th. The business services provider reported $1.10 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.14 by ($0.04). The firm had revenue of $883.00 million for the quarter, compared to analyst estimates of $896.81 million. Stericycle had a positive return on equity of 13.93% and a negative net margin of 0.79%. Stericycle’s quarterly revenue was down .8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.24 earnings per share.
In other Stericycle news, Director Mark C. Miller sold 19,753 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $64.03, for a total value of $1,264,784.59. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 79,012 shares of company stock worth $5,240,668. Corporate insiders own 3.50% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. AXA boosted its position in shares of Stericycle by 1,090.5% in the third quarter. AXA now owns 124,875 shares of the business services provider’s stock valued at $8,943,000 after acquiring an additional 114,386 shares during the period. GSA Capital Partners LLP bought a new stake in Stericycle during the third quarter worth about $532,000. Gofen & Glossberg LLC IL lifted its position in Stericycle by 2.7% during the third quarter. Gofen & Glossberg LLC IL now owns 65,415 shares of the business services provider’s stock worth $4,685,000 after purchasing an additional 1,724 shares during the period. IFM Investors Pty Ltd bought a new stake in Stericycle during the third quarter worth about $265,000. Finally, California Public Employees Retirement System lifted its position in Stericycle by 2.9% during the third quarter. California Public Employees Retirement System now owns 156,984 shares of the business services provider’s stock worth $11,243,000 after purchasing an additional 4,384 shares during the period. 94.63% of the stock is owned by institutional investors.
Shares of Stericycle (NASDAQ SRCL) traded up $1.02 on Friday, reaching $66.88. 1,179,880 shares of the company were exchanged, compared to its average volume of 827,871. The firm has a market capitalization of $5,638.02, a P/E ratio of 15.22, a price-to-earnings-growth ratio of 1.61 and a beta of 0.16. Stericycle has a fifty-two week low of $61.25 and a fifty-two week high of $88.00. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.82 and a current ratio of 0.82.
Stericycle Company Profile
Stericycle, Inc is a business-to-business services provider. The Company focuses on regulated and compliance solutions for healthcare, retail, and commercial businesses. The Company’s segments include Domestic and Canada Regulated Waste and Compliance Services (RCS), Domestic Communication and Related Services (CRS), International RCS and All other.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stericycle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stericycle and related companies with MarketBeat.com's FREE daily email newsletter.